September 16, 2025 — Morpeth, United Kingdom Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), has announced the addition of a state-of-the-art Korsch XM-12 bilayer tablet press at its Morpeth, UK facility. The new equipment enhances formulation capabilities, supporting the development of fixed-dose combinations and modified-release drug products. This strategic investment reinforces Piramal’s commitment to quality, innovation, and patient-centric solutions across global markets.
Science Significance
The Korsch XM-12 is designed to offer precision and flexibility in tablet production. It supports both single-layer and bilayer formulations, allowing researchers to develop advanced drug delivery systems. The press is equipped with advanced sanitary fittings, specialized product chutes for high-potency APIs, and fast-change turret systems to reduce downtime. This capability enables scientists to develop complex oral solid dosage forms, including modified-release and combination therapies. The precision offered by the XM-12 ensures consistent tablet weight and dosage, which is critical for clinical success and patient safety.
Regulatory Significance
Piramal Pharma Solutions has implemented rigorous training and validation protocols to ensure regulatory compliance. The XM-12 installation includes qualification and validation processes aligned with current Good Manufacturing Practices (cGMP) and industry standards. Operators, maintenance teams, and scientists are trained alongside factory experts to ensure safe handling and optimal output. The ability to maintain consistent precision with minimal operator interaction reduces the risk of human error, supporting product integrity and regulatory requirements.
Business Significance
Advertisement
The addition of the XM-12 bolsters Piramal’s formulation development capabilities, enabling high-output tablet production with increased efficiency. The press’s ability to handle diverse formulations allows for faster technical transfers, improved product development timelines, and cost-effective manufacturing. This investment strengthens Piramal’s position in global markets, helping pharmaceutical companies accelerate product launches. With rising demand for personalized therapies and complex drug delivery systems, the XM-12 provides a competitive edge by supporting scalable and reproducible manufacturing processes.
Patients’ Significance
For patients, the XM-12 enables the development of safer and more effective medications. The press’s precision ensures consistent dosing, which is essential for managing chronic diseases and complex treatments. Its capacity for modified-release formulations offers improved patient compliance by reducing dosing frequency. Moreover, by enabling high-quality fixed-dose combinations, the XM-12 helps simplify treatment regimens, offering better therapeutic outcomes and fewer side effects.
Policy Significance
The implementation of advanced technologies like the XM-12 reinforces the importance of innovation within regulated frameworks. Regulatory bodies prioritize patient safety and product consistency, and tools like this align with those expectations. Training protocols and validation procedures ensure compliance with safety standards, while promoting technological advancement in pharmaceutical manufacturing. These investments also support global health policies aimed at improving access to innovative treatments without compromising quality or efficacy.
The integration of the Korsch XM-12 bilayer tablet press marks a significant milestone in pharmaceutical manufacturing. Piramal’s Morpeth facility is now equipped to support advanced formulation development, enabling efficient and scalable production of complex therapies. This strategic move reflects a broader industry trend toward precision manufacturing and personalized medicine. By combining advanced technology with rigorous training and validation, Piramal Pharma Solutions continues to lead efforts in improving treatment accessibility, patient safety, and global health outcomes.
Source: Piramal Pharma Solutions Press Release
